MEMOTEXT will be tested for its effects on people with glaucoma. There will be 500 people recruited using telephone calls and text messages.
Amos Adler, president of MEMOTEXT, finds it to be an honor to collaborate on this special grant and believes this new interface will significantly improve medication adherence in patients with glaucoma. The company is confident this trial will demonstrate that their technology-driven adherence solutions help patients managing various conditions.
For more information on the trial, click here.
Thursday, January 15, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment